Science Magazine Podcast, 4/11/24: '
Trialing treatments for Long Covid...' (Transcript
here)
In this segment: Michael Peluso, Sara Cherry, Shelley Hayden
'Reporter Jennifer Couzin-Frankel takes a look at the different trials on the table to treat Long COVID'
'Sara Cherry, a virologist at the University of Pennsylvania has been studying how the virus interacts with different tissues in the body since the beginning of the pandemic. Now, she's looking for biomarkers, molecules, or other substances in the body that largely show up in people with Long COVID. If virus or antigens, viral fragments can be detected, they could help clinicians better track how well treatments work.'
'What we've also been trying to do is look in stool samples from Long COVID patients to see if we can continue to detect viral antigen, and if so, that will give us lots of information. Potentially, we can use that as a biomarker for treatments, watching to see if that goes away. There are other strategies being looked at to try to find remnants of the virus in various accessible tissues. Maybe then, we can be more careful or more thoughtful about which clinical trials we enroll, which patients in to potentially have a better efficacy.
MP: 'I had actually wanted to do a study of a monoclonal antibody for Long COVID basically from the moment that we identified that at least some people had these viral remnants. And a subset of people, we think that these remnants are intermittently present in blood, and if that's the case, they could almost act sort of like as a toxin. Setting off an immune response.'
JC: 'I think the hope is that we will see results from some of these small trials. By the end of this year, it's gonna be important to be thoughtful about how we interpret the results'
SH: In the meanwhile, people need support, and that looks like financial support, that looks like caregiving support, that looks like better training for Long COVID doctors. There needs to be some kind of immediate action to get some education in place so that people have better access to care until we do have treatments. There's not a day that goes by that I don't think about what this is like for the people who don't have family to support them or help them if they aren't able to support themselves anymore.'
SC: While patients like Shelly wait for answers, researchers also hope that what we learn from these trials can be used to better understand other chronic conditions that people develop after viral infections.
Megan Cantwell: 'So if we understand the mechanisms that drive Long COVID, we may then really be able to understand these other syndromes that we really knew very little about..'